Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma-Reference-Cited by-同舟云学术

Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma

Published:2021-11 Issue: Volume:158 Page:225-233
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Weber Jeffrey S.,Ascierto Paolo A.^ORCID,Middleton Mark R.^ORCID,Hennicken Delphine,Zoffoli Roberto^ORCID,Pieters Anne,Amadi Adenike,Kupas Katrin,Kotapati Srividya,Moshyk Andriy^ORCID,Schadendorf Dirk^ORCID

Funder

Ono Pharmaceutical

Bristol-Myers Squibb

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference19 articles.

1. Adjuvant therapy for melanoma;Agha;Curr Oncol Rep,2017

2. Systemic therapy for melanoma: ASCO guideline;Seth;J Clin Oncol,2020

3. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial;Eggermont;Lancet Oncol,2015

4. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy;Eggermont;N Engl J Med,2016

5. Adjuvant pembrolizumab versus placebo in resected stage III melanoma;Eggermont;N Engl J Med,2018

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adjuvant anti-PD1 immunotherapy of resected skin melanoma: an example of non-personalized medicine with no overall survival benefit;Critical Reviews in Oncology/Hematology;2024-10

2. Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238;Journal of Clinical Oncology;2024-08-05

3. Beyond Anti-PD-1/PD-L1: Improving Immune Checkpoint Inhibitor Responses in Triple-Negative Breast Cancer;Cancers;2024-06-11

4. Relationships between survival and real-world recurrence-free survival or distant metastasis-free survival among patients with completely resected stage IIB or IIC melanoma;Melanoma Research;2024-05-27

5. Adjuvant immunotherapy for melanoma patients: progress and opportunities;ESMO Open;2024-05